AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29965789 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete weightbearing restriction until week 7
Number of subjects: 75
Study 29965789 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete weightbearing restriction until week 7 with ankle joint mobilization exercises
Number of subjects: 75
Study 29965789 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weightbearing from day 1 and full weightbearing from week 5
Number of subjects: 75
Study 29965789 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups received the same home exercise guidelines starting from week 9
Number of subjects: 75
Study 27419258 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined oral contraceptives (COCs)
Number of subjects: 26
Study 27419258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24464122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration anesthesia with dermal filler injections
Number of subjects: 41
Study 24464122 — intervention group
Group type: COMPARATOR
Intervention: Dermal filler injections alone (Control)
Number of subjects: 41
Study 22580252 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 4688
Study 20031468 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-intensive multidisciplinary outpatient program (36 sessions, each lasting 2 hours)
Number of subjects: 262
Study 17589893 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.5 mg s.c. every 8 h for 6 weeks, followed by octreotide LAR 20 mg i.m. at week 4-8, and octreotide LAR 30 mg i.m. every 4 weeks thereafter)
Number of subjects: 127
Study 17589893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 16243985 — intervention group
Group type: EXPERIMENTAL
Intervention: FSNB with bupivacaine (0.125%) and clonidine (2 microg/kg)
Number of subjects: 36
Study 16243985 — intervention group
Group type: COMPARATOR
Intervention: IA with bupivacaine (0.25%) and clonidine (1 microg/kg) and morphine (5 mg)
Number of subjects: 36
Study 12175403 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous leuprorelin or goserelin (both LHRH analogues), cyproterone acetate (a steroidal antiandrogen)
Number of subjects: 82
Study 12175403 — intervention group
Group type: COMPARATOR
Intervention: Close clinical monitoring
Number of subjects: 82
Study 9657539 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg o.d.)
Number of subjects: 50
Study 9657539 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg o.d.)
Number of subjects: 50
Study 8075734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine information pamphlets
Number of subjects: 307
Study 2673323 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin with vacuum cleaning
Number of subjects: 4
Study 2673323 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo spray with vacuum cleaning
Number of subjects: 4
Study 2673323 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin without vacuum cleaning
Number of subjects: 4
Study 2673323 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo spray without vacuum cleaning
Number of subjects: 4
Study 2673323 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both interventions)
Number of subjects: 4
Study 4619836 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam in addition to standard treatment
Number of subjects: 200
Study 4619836 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 200
Study 30753861 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based educational intervention
Number of subjects: 1950
Study 30753861 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based educational intervention with free school fruit
Number of subjects: 1950
Study 30753861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1950
Study 27231835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (n=32)
Number of subjects: 64
Study 27231835 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n=32)
Number of subjects: 64
Study 25138736 — intervention group
Group type: EXPERIMENTAL
Intervention: H. persicum hydroalcoholic fruit extract (300 mg/day)
Number of subjects: 27
Study 25138736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24349890 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based EDO prevention curriculum
Number of subjects: 0
Study 24349890 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21719012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 144
Study 21719012 — intervention group
Group type: COMPARATOR
Intervention: Low-dose epidural analgesia (LEA)
Number of subjects: 144
Study 18638047 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive, lipid-lowering diet
Number of subjects: 50
Study 16847150 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive simvastatin therapy
Number of subjects: 3813
Study 16847150 — intervention group
Group type: COMPARATOR
Intervention: Delayed conservative simvastatin strategy
Number of subjects: 3813
Study 16847150 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L
Number of subjects: 3813
Study 16847150 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP 1 to 3 mg/L
Number of subjects: 3813
Study 12878372 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg/d for 1 week)
Number of subjects: 29
Study 10689518 — intervention group
Group type: EXPERIMENTAL
Intervention: Consta Vac
Number of subjects: 30
Study 10689518 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans
Number of subjects: 30
Study 10689518 — intervention group
Group type: EXPERIMENTAL
Intervention: Haem‐o‐Trans
Number of subjects: 30
Study 9499493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole (0.5 mg/kg body weight)
Number of subjects: 1094
Study 9499493 — intervention group
Group type: COMPARATOR
Intervention: Conventional pretreatment (heparin 15,000 I.E. and aspirin 500 mg i.v.)
Number of subjects: 1094
Study 9499493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole
Number of subjects: 1094
Study 7704933 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 0
Study 7704933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3315283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate
Number of subjects: 127
Study 3315283 — intervention group
Group type: COMPARATOR
Intervention: Oral methotrexate
Number of subjects: 127
Study 31491796 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (2,000 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Number of subjects: 92
Study 31491796 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (1,300 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Number of subjects: 92
Study 31585740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleuropein-enriched chocolate (40 g)
Number of subjects: 45
Study 31585740 — intervention group
Group type: COMPARATOR
Intervention: Control chocolate spread (40 g)
Number of subjects: 45
Study 29402577 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (GES)
Number of subjects: 30
Study 29402577 — intervention group
Group type: COMPARATOR
Intervention: Sham group (GS)
Number of subjects: 30
Study 28455172 — intervention group
Group type: EXPERIMENTAL
Intervention: One IPV dose at 14 weeks (SP‐1, GSK‐1, BBio‐1)
Number of subjects: 900
Study 28455172 — intervention group
Group type: EXPERIMENTAL
Intervention: Two IPV doses at 14 and 36 weeks (SP‐2, GSK‐2, BBio‐2)
Number of subjects: 900
Study 28455172 — intervention group
Group type: COMPARATOR
Intervention: One IPV dose
Number of subjects: 900
Study 28455172 — intervention group
Group type: COMPARATOR
Intervention: Two IPV doses
Number of subjects: 900
Study 28455172 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 900
Study 25336665 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Dallas lesion group (CPVI, posterior box lesion, and anterior linear ablation)
Number of subjects: 100
Study 25336665 — intervention group
Group type: COMPARATOR
Intervention: CPVI group
Number of subjects: 100
Study 25336665 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Dallas lesion group
Number of subjects: 100
Study 23183529 — intervention group
Group type: COMPARATOR
Intervention: PR48 (peginterferon-ribavirin for 44 weeks)
Number of subjects: 178
Study 23183529 — intervention group
Group type: EXPERIMENTAL
Intervention: BOC/RGT (boceprevir plus peginterferon-ribavirin using response guided therapy)
Number of subjects: 178
Study 23183529 — intervention group
Group type: EXPERIMENTAL
Intervention: BOC/PR48 (boceprevir plus peginterferon-ribavirin for 44 weeks)
Number of subjects: 178
Study 21803011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg
Number of subjects: 75
Study 21803011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 5.0 mg
Number of subjects: 75
Study 21803011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 75
Study 21803011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 19398460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus administration of meropenem (1 g 8 hourly)
Number of subjects: 10
Study 19398460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem (1 g)
Number of subjects: 10
Study 19398460 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosing regimens (intermittent bolus, extended, continuous infusion)
Number of subjects: 10
Study 19398460 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended or continuous infusion of meropenem
Number of subjects: 10
Study 16688496 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Well-Being Scale (QWB)
Number of subjects: 60
Study 16688496 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI3)
Number of subjects: 60
Study 16688496 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 60
Study 16688496 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 60
Study 16688496 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3
Number of subjects: 60
Study 16688496 — intervention group
Group type: EXPERIMENTAL
Intervention: All measures
Number of subjects: 60
Study 15496218 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg (oral) once daily from days 6 to 29
Number of subjects: 35
Study 11669506 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 11669506 — intervention group
Group type: COMPARATOR
Intervention: Conventional AChE inhibitors (rivastigmine and donepezil)
Number of subjects: 0
Study 9282800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial branches supplying HCC
Number of subjects: 72
Study 9282800 — intervention group
Group type: COMPARATOR
Intervention: Hepatic arterial branches not supplying HCC
Number of subjects: 72
Study 7685428 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 50 mg daily for 24 weeks
Number of subjects: 30
Study 7685428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7685428 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex
Number of subjects: 30
Study 3543239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (500 mg/m2 day 1), imidazole carboxamide (250 mg/m2 days 1 through 5), and doxorubicin (50 mg/m2 day 1)
Number of subjects: 76
Study 3543239 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2)
Number of subjects: 76
Study 3543239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 76
Study 31628838 — intervention group
Group type: EXPERIMENTAL
Intervention: High eAb-B titers
Number of subjects: 773
Study 31628838 — intervention group
Group type: COMPARATOR
Intervention: Low or medium eAb-B titers
Number of subjects: 773
Study 30179528 — intervention group
Group type: EXPERIMENTAL
Intervention: eTEST (HST kits with follow-up counseling)
Number of subjects: 65
Study 30179528 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard HST (HST kits with no follow-up)
Number of subjects: 65
Study 30179528 — intervention group
Group type: COMPARATOR
Intervention: Control (informational letters about HIV testing locations)
Number of subjects: 65
Study 27619827 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg long‐acting octreotide once every 4 weeks for 52 weeks, in addition to standard care
Number of subjects: 62
Study 27619827 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 62
Study 27619827 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg long‐acting octreotide
Number of subjects: 62
Study 24978156 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 18
Study 24978156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22288906 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry/Rumination Prime (WRP)
Number of subjects: 253
Study 22288906 — intervention group
Group type: COMPARATOR
Intervention: Neutral Prime (NP)
Number of subjects: 253
Study 22288906 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-priming (overall effect)
Number of subjects: 253
Study 20175874 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 71
Study 20175874 — intervention group
Group type: COMPARATOR
Intervention: Mini-sling
Number of subjects: 71
Study 18756741 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy leading to a decrease in NT-pro BNP levels
Number of subjects: 61
Study 18756741 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy leading to a decrease in TNF-alpha levels
Number of subjects: 61
Study 18756741 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy leading to a decrease in IL-6 levels
Number of subjects: 61
Study 15917043 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based supervisor training
Number of subjects: 176
Study 15917043 — intervention group
Group type: COMPARATOR
Intervention: Non-training group (control)
Number of subjects: 176
Study 12485787 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic control (slow, near-normal, near-ballistic)
Number of subjects: 6
Study 12485787 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic control
Number of subjects: 6
Study 12485787 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-ballistic walking (automatic control)
Number of subjects: 6
Study 12485787 — intervention group
Group type: COMPARATOR
Intervention: Hand-controlled walking
Number of subjects: 6
Study 10796063 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg enteric-coated aspirin
Number of subjects: 0
Study 10796063 — intervention group
Group type: COMPARATOR
Intervention: Regular aspirin
Number of subjects: 0
Study 8729092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of n-3 polyunsaturated fatty acids (PUFA) from fish oils
Number of subjects: 250000
Study 8729092 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) ingestion
Number of subjects: 250000
Study 8232855 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces (6 sec inspection)
Number of subjects: 33
Study 8232855 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces (20 sec inspection)
Number of subjects: 33
Study 8232855 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces (left/right inversion of stimuli)
Number of subjects: 33
Study 8232855 — intervention group
Group type: COMPARATOR
Intervention: Vases (6 sec and 20 sec inspection)
Number of subjects: 33
Study 3956107 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) at 0.1 m‐unit min‐1 kg‐1
Number of subjects: 10
Study 3956107 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) during tilting to 50 degrees
Number of subjects: 10
Study 3956107 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose AVP (0.0125 m‐unit min‐1 kg‐1)
Number of subjects: 10
Study 3956107 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose AVP (0.3 m‐unit min‐1 kg‐1)
Number of subjects: 10
Study 3956107 — intervention group
Group type: COMPARATOR
Intervention: 5% D‐glucose
Number of subjects: 10
Study 30171161 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg [14C]finerenone (single oral administration)
Number of subjects: 4
Study 29871045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid muscle flaps group
Number of subjects: 81
Study 29871045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 24248184 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg (1000 IU) vitamin D3
Number of subjects: 251
Study 24248184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg (400 IU) vitamin D3
Number of subjects: 251
Study 24248184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 22890226 — intervention group
Group type: EXPERIMENTAL
Intervention: etafilcon A
Number of subjects: 120
Study 22890226 — intervention group
Group type: EXPERIMENTAL
Intervention: narafilcon A
Number of subjects: 120
Study 22890226 — intervention group
Group type: EXPERIMENTAL
Intervention: senofilcon A
Number of subjects: 120
Study 21090563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg every 3 weeks for four doses)
Number of subjects: 115
Study 21090563 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic oral budesonide (9 mg/d with gradual taper through week 16)
Number of subjects: 115
Study 21090563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 115
Study 18675750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 60
Study 18675750 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 60
Study 18675750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16291162 — intervention group
Group type: EXPERIMENTAL
Intervention: Alimemazine (0.25 mg/kg 3 times a day, maximum 2.5 mg per dose)
Number of subjects: 15
Study 16291162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12891222 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (300 mL)
Number of subjects: 25
Study 12891222 — intervention group
Group type: COMPARATOR
Intervention: Control (no grapefruit juice)
Number of subjects: 25
Study 12891222 — intervention group
Group type: EXPERIMENTAL
Intervention: 6'7'-dihydroxybergamottin (in vitro)
Number of subjects: 25
Study 12891222 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamottin (in vitro)
Number of subjects: 25
Study 10224206 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T plus ddI (arm 3)
Number of subjects: 108
Study 10224206 — intervention group
Group type: COMPARATOR
Intervention: d4T alone (arm 2)
Number of subjects: 108
Study 10224206 — intervention group
Group type: COMPARATOR
Intervention: d4T monotherapy (arm 1)
Number of subjects: 108
Study 8722345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) administered as a 2-h infusion (60 mg/kg) for 2 days with MESNA as intermittent bolus infusion (20% of CY dose) every 6 h
Number of subjects: 20
Study 8722345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) administered by continuous infusion (1500 mg/m2/day) for 4 days with MESNA administered concomitantly at an equivalent dose to CY by continuous infusion
Number of subjects: 20
Study 1853147 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) at a dose of 15 mg/kg/day
Number of subjects: 12
Study 1853147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dose of 15 mg/kg/day
Number of subjects: 12
Study 1853147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CDCA and UDCA (7.5 + 7.5 mg/kg/day)
Number of subjects: 12
Study 6430666 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 mg nitroglycerin
Number of subjects: 12
Study 6430666 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg nitroglycerin
Number of subjects: 12
Study 6430666 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nitroglycerin
Number of subjects: 12
Study 6430666 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nitroglycerin
Number of subjects: 12
Study 6430666 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nitroglycerin (6 hours later)
Number of subjects: 12
Study 6430666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30500183 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest algorithm for virtual screening
Number of subjects: 22434
Study 30500183 — intervention group
Group type: COMPARATOR
Intervention: Multi-task neural networks
Number of subjects: 22434
Study 28918212 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (α-glucosidase inhibitor)
Number of subjects: 19
Study 28918212 — intervention group
Group type: COMPARATOR
Intervention: Control period (no miglitol)
Number of subjects: 19
Study 27194437 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraPro Hernia System
Number of subjects: 309
Study 27194437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System
Number of subjects: 309
Study 27194437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein procedure
Number of subjects: 309
Study 27194437 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 309
Study 24646172 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (brisk walking 20-min/day)
Number of subjects: 200
Study 24646172 — intervention group
Group type: COMPARATOR
Intervention: Dietary recommendations only
Number of subjects: 200
Study 24646172 — intervention group
Group type: COMPARATOR
Intervention: Behavioural dietary recommendations
Number of subjects: 200
Study 24646172 — intervention group
Group type: COMPARATOR
Intervention: Behavioural dietary recommendations + Exercise
Number of subjects: 200
Study 22093142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT) including lifestyle advice and strict regulation of metabolic parameters
Number of subjects: 183